Antiparkinsonian effect of flupirtine in monoamine-depleted rats

Journal of Neural Transmission

Volumn 103, Issue 5, 1996, Pages 581-590

  Schwarz, M ^a   Nolden Koch, M ^a   Purr, J ^a   Pergande, G ^b   Block, F ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b ASTA MEDICA AG   (Germany)

Author keywords

D methyl p tyrosine; EMG activity; Flupirtine; L DOPA; Locomotor activity; Monoamine depletion; Parkinson's disease; Rats; Reserpine

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; FLUPIRTINE; LEVODOPA; METIROSINE; MONOAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RESERPINE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GASTROCNEMIUS MUSCLE; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MUSCLE RIGIDITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RIGIDITY;

AMINOPYRIDINES; ANALGESICS; ANIMALS; ANTIPARKINSON AGENTS; BIOGENIC MONOAMINES; DRUG SYNERGISM; ELECTROMYOGRAPHY; LEVODOPA; MALE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE, SECONDARY; RATS; RATS, WISTAR;

EID: 0029849437     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01273155     Document Type: Article

References (34)

1. Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436-1438
2. Birkmayer W, Hornykiewicz O (1961) Der L-3,4-Dioxyphenyalanin (-DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787-788
3. Block F, Pergande G, Schwarz M (1994) Flupirtine protects against ischaemic retinal dysfunction in rats. NeuroReport 5; 2630-2632
4. Brotchie JM, Mitchell IJ, Sambrock MA, Crossman AR (1991) Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord 6: 133-138
5. Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221-226
6. Carlsson KH, Jurna I (1987) Depression by flupirtine, a novel analgesic agent, of motor and sensory responses of the nociceptive system in the rat spinal cord. Eur J Pharmacol 143: 89-99
7. Carlsson M, Svensson A, Carlsson A (1992) Interaction between excitatory amino acids, catecholamines and acetylcholine in the basal ganglia. In: Simon RP (ed) Excitatory amino acids. Thieme, New York, pp 189-194
8. Engber TM, Anderson JJ, Boldry RC (1993) N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with unilateral 6-hydroxydopamine lesion. Neuroscience 54: 1051-1061
9. Fahn S (1992) Adverse effects of levodopa. In: Olanow CW, Lieberman AN (eds) The scientific basis for the treatment of Parkinson's disease. Parthenon, Carnforth, pp 89-112
10. Filion M, Tremblay L (1991) Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 547: 142-151
11. Friedel HA, Fitton A (1993) Flupirtine: a review of its pharmacological properties and therapeutic efficacy in pain states. Drugs 45: 548-569
12. Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM (1994) Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 35: 655-661
13. Havemann U, Winkler M, Kuschinsky K (1980) Opioid receptors in the caudate nucleus can mediate EMG-recorded rigidity in rats. Naunyn Schmiedebergs Arch Pharmacol 313: 139-144
14. Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann Neurol 28: 539-546
15. Klockgether T, Turski L (1993) Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann Neurol 34: 585-593
16. Löschmann PA, Lange KW, Kunow M, Rettig KJ, Jähnig P, Honoré T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-DOPA in models of Parkinson's disease. J Neural Transm [PD-Sect] 3: 203-213
17. Maj J, Sowinska H, Baran L, Samek J (1974) Pharmacological effect of 1,3-dimethyl-5-amino-adamantane, a new adamantane derivative. Eur J Pharmacol 26: 9-14
18. Mitchell IJ, Clarke CE, Boyce S (1989) Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32: 213-226
19. Moore R, Bullingham RES, Simpson S, O'Sullivan G, Evans PJD, McQuay J (1983) Comparison of flupirtine maleate and dihydrocodeine in patients following surgery. Br J Anaesth 55: 429-432
20. Morelli M, Fenu S, Pinna A, Di Chiara G (1992) Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2- mediated behaviour in the 6-hydroxydopamine model of turning: relationship with c-fos expression. J Pharmacol Exp Ther 260: 402-408
21. Nickel B, Jakovlev V, Szelenyi I (1990) Effects of flupirtine, some analgesics and of muscle relaxants on sceletal muscle tone in conscious rats. Arzneimittelforschung/ Drug Res 40: 909-911
22. Osborne NN, Pergande G, Block F, Schwarz M (1994) Immunohistochemical evidence for flupirtine acting as an antagonist on the N-methyl-D-aspartate and homocysteic acid-induced release of GABA in the rat retina. Brain Res 667: 291-294
23. Osborne NN, Schwarz M, Pergande G (1996) Protection of rabbit retina from ischaemic injury by flupirtine. Invest Ophthalmol Vis Sci 37: 274-280
24. Perovic S, Schleger C, Pergande G, Iskric I, Ushijima H, Rytik P, Müller WEG (1994) The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1. Eur J Pharmacol 288: 27-33
25. Rogawski MA (1993) Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 14: 325-331
26. 2+ concentration. Eur J Pharmacol 294: 469-473
27. Schmidt WJ, Bubser M (1989) Anticataleptic effects of N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32: 621-623
28. Schmidt WJ, Bubser M, Hauber W (1992) Behavioural pharmacology of glutamate in the basal ganglia. J Neural Transm 38 [Suppl]: 65-89
29. Scholz E, Diener HC, Noth J, Friedemann H, Dichgans J, Bacher M (1986) Medium and long latency EMG responses in leg muscles: Parkinson's disease. J Neurol Neurosurg Psychiatry 50: 66-70
30. Schwarz M, Block F, Pergande G (1994) N-methyl-D-aspartate (NMDA) mediated muscle relaxant action of flupirtine in rats. NeuroReport 5: 1981-1984
31. 2-adrenergic mechanisms are involved in the depressant action of flupirtine on spinal reflexes in rats. Eur J Pharmacol 276: 247-255
32. Shahani BT, Young RR (1971) Human flexor reflexes. J Neurol Neurosurg Psychiatry 34: 616-627
33. Steg G (1964) Efferent muscle innervation and rigidity. Acta Physiol Scand [Suppl] 223: 1-53
34. Timmann D, Plummer C, Schwarz M, Diener HC (1995) Influence of flupirtine on human lower limb reflexes. Electroencephalogr Clin Neurophysiol 97: 184-188